Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$178.2B
1,240M shares
52-week range
$108.46 – $157.29
75% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
P/S (TTM)
5.9
EV / FCF (TTM)
15.4
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
www.gilead.comNo one on the platform currently holds GILD.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,152,528 | $300.0M |
| Bridgewater Associatesas of 2026-03-31 | 180,737 | $25.2M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-09-15 | $0.8200 | 2026-09-29 |
| 2026-06-15 | $0.8200 | 2026-06-29 |
| 2026-03-13 | $0.8200 | 2026-03-30 |
| 2025-12-15 | $0.7900 | 2025-12-30 |
| 2025-09-15 | $0.7900 | 2025-09-29 |
| 2025-06-13 | $0.7900 | 2025-06-27 |
| 2025-03-14 | $0.7900 | 2025-03-28 |
| 2024-12-13 | $0.7700 | 2024-12-30 |
| 2024-09-13 | $0.7700 | 2024-09-27 |
| 2024-06-14 | $0.7700 | 2024-06-27 |
No one on the platform has traded GILD yet.
| 2024-03-14 | $0.7700 | 2024-03-28 |
| 2023-12-14 | $0.7500 | 2023-12-28 |
| Execution date | Ratio |
|---|---|
| 2013-01-28 | 2-for-1 |
| 2007-06-25 | 2-for-1 |
| 2004-09-07 | 2-for-1 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 25.4% | 15.0% | 15.5% | — | — | — |
| Rev. Growth % | 2.4% | 3.6% | ||||
| Profit Margin % | 28.9% | 18.2% | 20.2% | |||
| Free Cash Flow Margin % | 32.1% | 33.1% | 36.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
Also held through funds
2 more books hold GILD indirectly · AVUS 0.4% of fund, VTI 0.2% of fund
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $30.7B | +5.0% | $-0.44 | $-0.60–$-0.30 | — | 16 |
| 2027 | $32.7B | +6.5% | $9.89 | $9.38–$11.07 | 14.6× | 16 |
| 2028 | $34.4B | +5.2% | $10.66 | $9.15–$12.17 | 13.6× | 10 |
| 2029 | $36.9B | +7.3% | $12.04 | $11.64–$12.55 | 12.0× | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $-7.25 | $-6.75 | +6.9% |
| 2026-05-07 | $1.91 | $2.03 | +6.3% |
| 2026-02-10 | $1.81 | $1.86 | +2.8% |
| 2025-10-30 | $2.13 | $2.47 | +16.0% |
| 2025-08-07 | $1.96 | $2.01 | +2.6% |
| 2025-04-24 | $1.78 | $1.81 | +1.7% |
| 2025-02-11 | $1.74 | $1.90 | +9.2% |
| 2024-11-06 | $1.53 |
| $2.02 |
| +32.0% |
| $142.9B |
| — |
| GSKGSK plc | $50.05 | +4.00% | $100.3B | — |
| MRKMerck & Co., Inc. | $144.84 | +0.63% | $357.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$SLS I wonder how many of the Inch Thick Mile Wide Retail Lemmings Know Final SLS009 Phase 2 Data for AML-MR Patients Published at ASH -- is better than the Magrolimab P1B AML-MR data published at ASH that $GILD bought for $4.9B - Just the Secondary Asset SLS009 / Tambiciclib, completed a 87 Patient Phase 1 trial in 7 Hematological Cancers, and Completed a Phase 2 Trial that achieved better survival (4x Os over Soc) and safety data than a drug that got bought for $4.9B by $GILD, and AND --- AND is Now in an • Phase 2 AMLMR Expansion Trial at the Request of FDA: • 80 patients • dual arm • Randomized and • Pivotal • with FDA Greenlight Data incoming next quarter – in Q4 • list FDA approved drugs based on Ph1/2 data like the trial 009 is now in.
View on StockTwits ↗$SLS Does everyone Realize - SLS009 / Tambiciclib, completed a 87 Patient Phase 1 trial in 7 Hematological Cancers, and Completed a Phase 2 Trial that achieved better survival (4x Os over Soc) and safety data than Magrolimab, PH1B data that Got bought for $4.9B by $GILD, and 009 is Now in an • expansion Phase 2 AML_MR trial at the request of FDA: • 80 patients • dual arm trial • Randomized and • Pivotal • with FDA greenlight data incoming next quarter – in Q4 • list FDA approved drugs based on Ph1/2 data like the trial 009 is now in.
View on StockTwits ↗$SLS Someone was asking about SLS009 Comps: Again SLS Published AML-MR Phase 2 Data at ASH: - 4X OS Advantage 57% ORR in TP53 End Stage Dying AML Patients which is better than the P1B AML-MR Magrlimab Data $GILD bought for $5B . ... Just the secondary asset is ALREADY Worth 2x 3x the current $2.33B Mcap.
View on StockTwits ↗
$KYTX We have institutional and insider ownership of only 69%. Gilead reported about 4.13M shares/~6.7%, making it one of KYTX's largest shareholders. Hopefully, $GILD buys us out soon.
View on StockTwits ↗$SLS $RVMD SLS009 / Tambiciclib at the request of FDA, is now in an expansion Phase 2 trial for AML-MR patients - the most Dire AML prognosis - with no treatment options. 80 patients Dual Arm trial Randomized and PIVOTAL -- with FDA greenlight data incoming next quarter – in Q4. -- and We already know the results from the Prior Phase 2: 4X MOS Advantage - No Toxicity. https://www.biospace.com/deals/merck-to-buy-terns-unprecedented-leukemia-drug-for-6-7b-as-keytruda-cliff-looms SLS009 Phase 2 AML-MRdata data previously published at Ash is better than Magrolimab $FTSV Ph1 AML-MR data published at Ash that $GILD paid $5B for … just the “secondary asset” SLS009 is already worth 2x 3x the current manipulated $2.6B mcap—-
View on StockTwits ↗$SLS $MRNA SLS009 Phase 2 AML-Mr Fata previously published at Ash is better than Magrolimab $FTSV Ph1 AML-MR data published at Ash that $GILD paid $5B for … just the ’/“secondary asset” SLS009 is already worth 2x 3x the current manipulated $2.6B mcap—- SLS009 / Tambiciclib at the request of FDA, is now in an expansion Phase 2 trial for AML-MR patients - the most Dire AML prognosis - with no treatment options. 80 patients Dual Arm trial Randomized and PIVOTAL -- with FDA greenlight data incoming next quarter – in Q4. -- and We already know the results from the Prior Phase 2: 4X MOS Advantage - No Toxicity.
View on StockTwits ↗
@TradeSun I see $GILD as absolute #1. why didn’t you include them?
View on StockTwits ↗
$KYTX the first patient ever treated is now well past 2yrs and remains in drug free remission. Plus they have an RMAT designation from the FDA for indication for Multiple Sclerosis. I wouldn’t be surprised if any of the following attempt to acquire $GILD already owns an equity stake, $NVS or $BMY both had to stop their CAR-T clinical trials.
View on StockTwits ↗$KYTX single most important line from the Wells Fargo conference “first patients…treated through the compassionate use program…before we started our pivotal clinical study, are now out past two years. They are still drug free, and in remission…” $GILD
View on StockTwits ↗$KYTX did some fact finding and Kyverna has historically issued PRs on Thursdays. My assumption is we get the PR post conference schedule on 9/17 or 9/24 and at latest 10/1 which is just after the AANEM conference. I haven’t seen them on the schedule for AANEM yet so if they don’t get on the schedule for those then the prior dates are likely a go. $GILD
View on StockTwits ↗
$JNJ $AMGN $AZN $GILD $PFE SEP 11 PDUFA for Midcap Oncology Biotech TLX (Friday), below.
View on StockTwits ↗
$GILD opened a new 182,000-sq-ft research center in Foster City, expanding its oncology, inflammation and data-science capabilities. https://www.rapidticker.com/news/gild-gilead-opens-state-of-the-11b08f
View on StockTwits ↗
@mike755 because of where the stock is, granted derisking needed to happen first. But looking on Reddit the speculation of an acquisition was already bounced around dismissed years ago. Now that I’ve had time to look into $GILD pattern and the fact that they have a large CAR-T biz plus an investment in $KYTX already I believe the odds increasing a lot now that they’re close to submitting the BLA.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.